Get the Stockscreener App
3.05
3.17%
-0.10
After Hours:
3.00
-0.05
-1.64%
AIM ImmunoTech Inc stock is traded at $3.05, with a volume of 475.08K.
It is down -3.17% in the last 24 hours and down -65.73% over the past month.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$3.15
Open:
$3.16
24h Volume:
475.08K
Relative Volume:
0.90
Market Cap:
$2.33M
Revenue:
$202.00K
Net Income/Loss:
$-28.96M
P/E Ratio:
-5.0833
EPS:
-0.6
Net Cash Flow:
$-21.85M
1W Performance:
-64.33%
1M Performance:
-65.73%
6M Performance:
+1,417%
1Y Performance:
+778.46%
1-Day Range:
$3.00
$3.39
1-Week Range:
$2.92
$20.35
52-Week Range:
$0.0633
$20.35
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
Compare AIM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
3.05 | 2.41M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
AIM ImmunoTech Inc Stock (AIM) Latest News
Biotech Alert: Searches spiking for these stocks today - TipRanks
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering - GlobeNewswire
Evaluating AIM ImmunoTech's Capital Raise: A Strategic Crossroads for Investors - AInvest
AIM Shares Fall After Pricing of $8 Million Public Offering - MarketScreener
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views - Benzinga
AIM ImmunoTech stock plunges after pricing $8 million public offering - Investing.com Australia
US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings - Benzinga
AIM ImmunoTech prices $8 million public offering at $4.00 per share - Investing.com
AIM ImmunoTech Plunges 51.11% Amid Market Volatility - AInvest
AIM ImmunoTech prices 2M shares at $4.00 in public offering - TipRanks
AIM ImmunoTech Secures Fresh Capital: $8M Offering Includes Dual Warrant Structure at $4.00 - Stock Titan
AIM ImmunoTech Inc Plunges 38.33% Amid Trading Halt - AInvest
AIM ImmunoTech Stock Plunges 40.97% on Volatility - AInvest
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
AIM ImmunoTech Reports Positive Mid-year Safety and - GlobeNewswire
AIM ImmunoTech Inc. Trading Resumes: Enhanced Tools and Expert Analysis Available for Investors - AInvest
Crude Oil Gains 2%; CEA Industries Shares Spike Higher - Benzinga
Why Is Micro-Cap AIM ImmunoTech Stock Surging? - Benzinga
AIM ImmunoTech's Ampligen: A Promising Catalyst for Shareholder Value in Pancreatic Cancer Therapy - AInvest
US Stocks Mixed; Enterprise Products Partners Posts Upbeat Earnings - Benzinga
AIM ImmunoTech Reports Positive Phase 2 Study Results - TipRanks
AIM ImmunoTech (AIM) reveals positive Phase 2 Ampligen pancreatic data | AIM SEC FilingForm 8-K - Stock Titan
Breakthrough in Pancreatic Cancer Treatment: New Phase 2 Data Shows 64% Survival Rate at 6 Months - Stock Titan
AIM ImmunoTech (NYSE:AIM) Stock Price Down 4.5% – Here’s What Happened - Defense World
Latest News - Asia Food Journal
AIM ImmunoTech granted U.S. patent for Ampligen - MSN
Omega Therapeutics (NASDAQ:OMGA) versus AIM ImmunoTech (NYSE:AIM) Head-To-Head Review - Defense World
AIM ImmunoTech Announces Recent Presentation on the - GlobeNewswire
AIM ImmunoTech (NYSE:AIM) Shares Gap Up – Here’s What Happened - Defense World
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements - The Manila Times
AIM ImmunoTech Faces NYSE Delisting Risk: $3.9M Deficit Triggers Second Warning - Stock Titan
AIM ImmunoTech resumes trading on NYSE American By Investing.com - Investing.com India
AIM ImmunoTech resumes trading on NYSE American - Investing.com
AIM ImmunoTech Resumes Trading on NYSE American - The Manila Times
AIM ImmunoTech Inc. Common Stock Resumes Trading on NYSE American - Nasdaq
Aim Immunotech CEO Thomas Equels acquires $823 in common stock By Investing.com - Investing.com India
Aim Immunotech CEO Thomas Equels acquires $823 in common stock - Investing.com
Aim Immunotech CEO Thomas Equels acquires shares worth $896 By Investing.com - Investing.com Nigeria
Aim Immunotech CEO Thomas Equels acquires shares worth $896 - Investing.com Australia
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension - GlobeNewswire
AIM ImmunoTech Regains NYSE Compliance, Stock Reinstated - TipRanks
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen® - The Manila Times
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, ... - Bluefield Daily Telegraph
New Patent Grant Extends Ampligen Manufacturing Protection for 18 Years: Major Win for Cancer and COVID Drug - Stock Titan
NYSE American Lifts AIM ImmunoTech Trading Ban After Stock Price Recovery - Stock Titan
AIM ImmunoTech Inc. Announces 1-for-100 Reverse Stock Split Effective June 12, 2025 - Nasdaq
Aim Immunotech Announces 1-For-100 Reverse Stock Split - MarketScreener
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split - GlobeNewswire
AIM ImmunoTech Sets Massive 1:100 Reverse Split to Save NYSE American Listing - Stock Titan
AIM ImmunoTech Inc Stock (AIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):